内分泌治疗后用于转移性乳腺癌的曲妥珠单抗德鲁昔单抗

Bardia 等人（Sat，）研究了该问题。

www.synapsesocial.com/papers/68e587feb6db643587524983 — DOI: https://doi.org/10.1056/nejmoa2407086

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Endocrine and Targeted Therapy for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer—Capivasertib-Fulvestrant: ASCO Rapid Recommendation Update· 2024 · 46 citations
2. MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer· 2019 · 671 citations
3. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1· 2016 · 1,090 citations
4. RIBBON-1: Randomized, Double-Blind, Placebo-Controlled, Phase III Trial of Chemotherapy With or Without Bevacizumab for First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative, Locally Recurrent or Metastatic Breast Cancer· 2011 · 1,058 citations
5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,240 citations